A Phase 1 safety and feasibility with HIV-positive individuals to test the T cells generated after using MVA-VLP HIV vaccine
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs MVA-VLP-HIv-Vaccine/lentivirus-therapy-AGT/GeoVax (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 12 Apr 2017 According to an American Gene Technologies International media release, company intends to initiate this trial later in 2017.
- 03 Apr 2017 New trial record
- 14 Mar 2017 According to a GeoVax Labs media release, company has collaboration with American Gene Technologies International Inc. (AGT) for this trial.